Loading clinical trials...

TERMINATEDPHASE2

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

A Phase IIa, Multicenter, Randomized, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of MK0974 for Migraine Prophylaxis in Patients With Episodic Migraine

NCT00797667•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient is 18 years of age or older
•Patient has had a history of migraine with or without aura
•Patient is able to complete study questionnaire(s) and paper diary

Exclusion Criteria

•Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study
•Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions
•Patient was older than 50 years of age at migraine onset
•History of gastric or small intestinal surgery or has a disease that causes malabsorption
•Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study
•Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study
•Currently participating in a study with MK-0974 or MK-3207

Key Dates

Start Date

November 12, 2008

Primary Completion Date

May 20, 2009

Completion Date

May 20, 2009

Last Updated

October 18, 2018

Enrollment

660

ACTUAL participants

Conditions

Migraine

Interventions

Telcagepant 140 mg

DRUG

Telcagepant 280 mg

DRUG

140 mg telcagepant placebo

DRUG

280 mg telcagepant placebo

DRUG

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

NCT07018713

Chronic Migraine

View study

RECRUITINGPHASE3

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

NCT06641466

Menstrual Migraine

View study

RECRUITINGNA

Mind Body Balance for Pediatric Migraine

NCT04715685

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 18, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

Inclusion Criteria

Exclusion Criteria

A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine

A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

Mind Body Balance for Pediatric Migraine

Light Exposure, Migraine Outcomes, and Sleep Quality

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Prophylactic Treatment With Atorvastatin for Episodic Migraine.